Status unknownNCT05833698AUDRIPUpdated Apr 27, 2023

Acute Uncomplicated Diverticulitis and Conservative Treatment: Accuracy of Inflammatory Indexes for Failure Prediction: Observational Prospective Cohort Study. (AUDRIP Trial)

An observational study in Acute Uncomplicated Diverticulitis, sponsored by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-27.

Sponsored by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Observational

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Not yet recruiting — may be out of date.

Study type: Observational
Model: Case-control
Time perspective: Prospective
Enrollment: 2,160
Ages: 18 Years and older
Sex: All

Study summary

This is an observational multicenter study that will analyse the accuracy of inflammatory indexes as neutrophil-lymphocyte ratio and platelet-lymphocyte ratio, to predict the failure of conservative treatment of patients diagnosed of acute uncomplicated diverticulitis.

Conditions studied

Acute Uncomplicated Diverticulitis

Browse trials for

Diverticulitis 125

In context

Diverticulitis

125 studies on the registry are indexed under Diverticulitis; 22 are open to participants now.

This study's planned enrollment of 2,160 is above the median of 275 across 59 observational studies indexed under Diverticulitis.

Browse Diverticulitis studies →

Lead sponsor

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa is the lead sponsor of 35 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: Yes
Sampling method: Non-probability sample

Study population

All patients over 18 years, diagnosed of acute uncomplicated diverticulitis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients older than 18, diagnosed of acute uncomplicated diverticulitis.
Diagnosis made by CT or ultrasound

Exclusion criteria

Exclusion Criteria:

Patients younger than 18.
Patients diagnosed of acute complicated diverticulitis

Study design

Observational model: Case-control
Time perspective: Prospective
Enrollment: 2,160 participants (estimated)
Patient registry: No

Groups and cohorts

Patients with failure of conservative treatment
Diagnostic Test: Elevation of NLR
Patients without failure of conservative treatment
Diagnostic Test: Elevation of NLR

Interventions

Diagnostic testElevation of NLR
Blood test
Also known as: Elevation of PLR

What researchers measure

Primary outcomes

Failure of conservative treatment with antibiotics
Time frame: 15th june 2023-31st december 2024
Failure of conservative treatment without antibiotics
Time frame: 15th june 2023-31st december 2024

Secondary outcomes

Evaluate the accuracy of PLR and NLR as predictors of failure
Time frame: 15th june 2023-31st december 2024
Analysis of trends in managemente of acute uncomplicated diverticulitis
Time frame: 15th june 2023-31st december 2024

Study locations

1 site

Hospital Universitario de La Princesa
Madrid, 28060, Spain

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for Mar 2024, 9 months later.

Of 22 observational studies under Diverticulitis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 101. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered: Apr 16, 2023
First posted: Apr 27, 2023
StartEst.: Jun 15, 2023
Primary completionEst.: Mar 31, 2024
CompletionEst.: Dec 31, 2024
Last update: Apr 27, 2023

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Apr 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05833698
Lead sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Responsible party: Alba Correa Bonito (MD, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa) — Principal investigator
First posted: Apr 27, 2023
Start date: Jun 15, 2023 (estimated)
Primary completion: Mar 31, 2024 (estimated)
Completion: Dec 31, 2024 (estimated)
Last update: Apr 27, 2023

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Diverticulitis →

Other studies from this sponsor

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Start the discussion